Jefferies analyst David Steinberg lowered estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $172.00 (from $224.00) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISINovember 2, 2015 9:04 PM Dead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?November 2, 2015 3:17 PM Goldman Sachs Downgrades Valeant Pharmaceuticals (VRX) to NeutralNovember 2, 2015 6:34 AM Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come MondayNovember 1, 2015 7:32 PM Valeant Pharmaceuticals (VRX) Bull-Bear Debate RagesOctober 30, 2015 12:57 PM